PureTech News

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Appoints UBS as Corporate Broker

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech to Present at Two Upcoming Investor Conferences

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round